Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · IEX Real-Time Price · USD
37.38
-1.43 (-3.68%)
At close: Jul 2, 2024, 4:00 PM
37.75
+0.37 (0.99%)
After-hours: Jul 2, 2024, 4:47 PM EDT

Revolution Medicines Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018 - 2017
Revenue
11.5835.3829.3942.9850.04
Upgrade
Revenue Growth (YoY)
-67.27%20.38%-31.62%-14.10%148.16%
Upgrade
Gross Profit
11.5835.3829.3942.9850.04
Upgrade
Selling, General & Admin
75.6240.5930.4521.4312.41
Upgrade
Research & Development
423.14253.07186.95132.2591.76
Upgrade
Operating Expenses
498.77293.66217.4153.68104.16
Upgrade
Operating Income
-487.19-258.28-188.01-110.7-54.12
Upgrade
Interest Expense / Income
0.300.010.070.11
Upgrade
Other Expense / Income
-47.6-9.15-0.93-2.24-2.19
Upgrade
Pretax Income
-439.89-249.13-187.09-108.53-52.04
Upgrade
Income Tax
-3.52-0.420-0.37-4.37
Upgrade
Net Income
-436.37-248.71-187.09-108.16-47.66
Upgrade
Preferred Dividends
0002.2214.24
Upgrade
Net Income Common
-436.37-248.71-187.09-110.38-61.9
Upgrade
Shares Outstanding (Basic)
1138173553
Upgrade
Shares Outstanding (Diluted)
1138173553
Upgrade
Shares Change
40.34%10.74%32.68%1879.17%20.61%
Upgrade
EPS (Basic)
-3.86-3.08-2.57-2.01-22.33
Upgrade
EPS (Diluted)
-3.86-3.08-2.57-2.01-22.33
Upgrade
Free Cash Flow
-358.3-235.22-153.71-103-52.01
Upgrade
Free Cash Flow Per Share
-3.17-2.92-2.11-1.88-18.76
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Upgrade
Operating Margin
-4207.12%-730.01%-639.70%-257.54%-108.15%
Upgrade
Profit Margin
-3768.28%-702.95%-636.58%-256.79%-123.70%
Upgrade
Free Cash Flow Margin
-3094.14%-664.83%-522.99%-239.62%-103.93%
Upgrade
EBITDA
-430.28-239.47-179.75-101.91-48.59
Upgrade
EBITDA Margin
-3715.71%-676.85%-611.59%-237.10%-97.10%
Upgrade
Depreciation & Amortization
9.319.667.336.553.34
Upgrade
EBIT
-439.59-249.13-187.08-108.46-51.93
Upgrade
EBIT Margin
-3796.10%-704.14%-636.54%-252.33%-103.78%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).